IP Library › Granted Patent US 12,612,417
Granted Patent B2
US 12,612,417 · App. 17/785,205 · Granted Apr 28, 2026

Deuterated analogues of selenophenochromenes, synthesis thereof, and methods of using same agents

Inventor: Pavels Arsenjans (Riga, LV)
Assignee: Latvian Institute of Organic Synthesis
C07D517/04A61K31/496A61K45/06A61P35/00C07B2200/05
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,612,417
App. No.
17/785,205
Granted
Apr 28, 2026
Kind
B2
Abstract

The present invention relates to a novel cancer curing deuterated selenopheno [h] chromene derivatives, as well as methods of their manufacturing and use in different pharmaceutical compositions for the treatment of cancer by administration of such substances.

Claims (10)

1 . A compound of formula (I), wherein the compound of formula (I) is:

2 . The compound according to claim 1 , wherein the compound has the structure:

3 . The compound according to claim 1 , wherein the compound has the structure:

4 . A pharmaceutical composition comprising the compound according to claim 1 and a pharmaceutically acceptable carrier.

5 . The pharmaceutical composition according to claim 4 , wherein the composition is a mono-phasic pharmaceutical composition suitable for parenteral or oral administration consisting essentially of a therapeutically effective amount of the compound of formula I, and a pharmaceutically acceptable carrier.

6 . A method of treating cancer, comprising administering a therapeutically effective amount of the compound of claim 1 to a patient in need thereof.

7 . The method of claim 6 , wherein the cancer is breast, sarcoma, fibrosarcoma, or lung cancer.

8 . The method of claim 6 , wherein the compound is administered in conjunction with one or more chemotherapeutic agents, surgery, chemotherapy, radiation, immunotherapy, or combinations thereof.

9 . The method of claim 6 , wherein the compound is

10 . The method of claim 6 , wherein the compound is

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 19, 2026
From: LATVIAN INSTITUTE OF ORGANIC SYNTHESIS
To: NATIONAL INSTITUTE OF RESEARCH AND INNOVATION
Reel/Frame 075708/0308 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 28, 2022
From: ARSENJANS, PAVELS
To: LATVIAN INSTITUTE OF ORGANIC SYNTHESIS
Reel/Frame 061586/0420 →
Priority Claims (1)
LV P-19-75 · Dec 20, 2019 · national
Continuity (1)
Related Publication 20230002411A1 · Jan 5, 2023
References Cited (16)
US 20190298758A1 · Arsenjans et al. · 2019 [cited by applicant]
AU 2018234985 · 2019 [cited by applicant]
EP 3492470 · 2019 [cited by applicant]
WO WO2012158885 · 2012 [cited by applicant]
WO WO2018015788 · 2018 [cited by applicant]
WO WO2018015788A1 · 2018 [cited by examiner]
WO WO2018167203 · 2018 [cited by applicant]
WO WO2019183403 · 2019 [cited by applicant]
Tung et al. Deuterium Medicinal Chemistry: A New Approach to Drug Discovery and Development, MEDCHEM News, May 2014, pp. 8-22. (Year: 2014). [cited by examiner]
Avanir.com [online], “Avanir Pharmaceuticals, Inc. Reports Phase 3 Data Evaluating Investigational AVP-786 for the Treatment of Moderate-to-Severe Agitation in Patients with Alzheimer's Dementia,” Mar. 2019, retrieved J… [cited by applicant]
ClinicalTrials.gov [online], “First-in-Human Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of VX-984 in Combination With Chemotherapy,” NCT02644278, last updated Sep. 9, 2019, retrieved … [cited by applicant]
International Search Report and Written Opinion in International Appln. No. PCT/IB2020/056817, dated Oct. 16, 2020, 8 pages. [cited by applicant]
Khan et al., “VX-984 is a selective inhibitor of non-homologous end joining, with possible preferential activity in transformed cells,” Oncotarget, May 2018, 9(40):25833-41. [cited by applicant]
Schmidt, “First deuterated drug approved,” Nat. Biotechnol., Jun. 2017, 35(6):493-94. [cited by applicant]
Siegel et al., “Cancer statistics, 2019,” CA Cancer J. Clin., Jan. 2019, 69(1):7-34. [cited by applicant]
Fukuto et al., “Determination of the mechanism of demethylenation of (methylenedioxy) phenyl compounds by cytochrome P450 using deuterium isotope effects,” Journal of Medicinal Chemistry, Sep. 1991, 34(9):2871-6. [cited by applicant]